Clinical trials: Glucagon
Overweight and Obesity, Healthy
A Study to Evaluate the Safety and Efficacy of NG101 in Adult Participants Receiving a Glucagon-like Peptide-1 (GLP-1) Agonist
Adult participants with BMI between 22 - 35 kg/m2 will be enrolled and randomized to receive either NG101 (20 mg twice daily [BID]) or placebo for 5 days beginning on Day 1.
- Trial name
- NCT06500429
- Testing
- NG101, Semaglutide Injectable Product
- Where
- United States
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- Neurogastrx, Inc.
Diabetic Kidney Disease, Type 1 Diabetes
Trial of Semaglutide for Diabetic Kidney Disease in Type 1 Diabetes
The primary objective of this study is to determine the effects of semaglutide on change in albuminuria from baseline to 26 weeks in type 1 diabetes.
- Trial name
- RT1D (NCT05822609)
- Testing
- Semaglutide
- Where
- 4 sites in United States, Canada
- Volunteers
- 60 people
- Sponsor
- University of Washington
Type I Diabetes Mellitus
Glutamine and Insulin Sensitivity in Type I Diabetes
Insulin is crucial to help the body metabolize ('burn') sugar (glucose). Even though juvenile (type 1) diabetes (T1D) is primarily due to the lack of insulin, patients with T1D tend to become less sensitive to insulin…
- Trial name
- NCT01467063
- Testing
- Glutamine
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- Nemours Children's Clinic
Type 2 Diabetes Mellitus
Tofogliflozin GLP-1 Analogue Combination Trial
An open-label, multicenter study to evaluate 52-week long-term safety, tolerability and efficacy of Tofogliflozin with GLP-1 analogue treatment in type 2 diabetes mellitus.
- Trial name
- NCT02537834
- Testing
- Tofogliflozin, GLP-1 analogue
- Where
- 11 sites in Japan
- Volunteers
- 65 people
- Sponsor
- Kowa Company, Ltd.
Diabetes Mellitus, Type 2, Kidney Disease, Chronic
Semaglutide's Effect on Renal Hemodynamics and Function in Patients With Type 2 Diabetes Mellitus and Nephropathy
The goal of this double-blinded, placebo-controlled, randomized, crossover study is to examine the effect of semaglutide, a glucagon-like peptide-1 receptor agonist (GLP-1RA), on renal hemodynamics and function in patients with…
- Trial name
- Sema-RMA (NCT06555146)
- Testing
- Semaglutide, 0.5 mg/mL
- Where
- Denmark
- Volunteers
- 15 people
- Sponsor
- Bispebjerg Hospital
Type 2 Diabetes
A Phase 3 Study to Evaluate Efficacy and Safety of HDM1002 Tablets in Adults With Type 2 Diabetes Mellitus
This is a multicenter, randomized, double-blind, active-controlled, parallel-group study, which aims to provide data on the efficacy and safety of HDM1002 tablets compared with dapagliflozin in adults with type 2 diabetes…
- Trial name
- NCT07082114
- Testing
- HDM1002 100 mg, HDM1002 200 mg, HDM1002 400 mg
- Where
- China
- Volunteers
- 800 people
- Sponsor
- Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.
Diabetes Mellitus, Type 2, Diabetes
The Effect of Simple Basal Insulin Titration, Metformin Plus Liraglutide for Type 2 Diabetes With Very Elevated HbA1c - The SIMPLE Study
The aim of this clinical trial is to assess and compare the effect of insulin detemir in combination with liraglutide and metformin versus insulin detemir in combination with insulin aspart and metformin in subjects with very…
- Trial name
- SIMPLE (NCT01966978)
- Testing
- Metformin, Detemir, Liraglutide
- Where
- United States
- Volunteers
- 157 people
- Sponsor
- University of Texas Southwestern Medical Center
Diabetes Mellitus, Diabetic Kidney Disease
Basal Plus GLP1-ra on Glycemic Variability in CKD
To compare GLP-1 RA plus basal insulin (BGLP) versus basal-bolus (BB) insulin regimens on glycemic variability (GV) and time in range (TIR) in diabetes patients CKD stage 3-4
- Trial name
- NCT05218915
- Testing
- Dulaglutide, Insulin Degludec, Continuous glucose monitor
- Where
- Hong Kong
- Volunteers
- 95 people
- Sponsor
- Elaine Chow
Obesity
To Determine Tolerability to Glucagon Infusion in Obese Subjects
To further understand the tolerability of glucagon.
- Trial name
- GIO (NCT02817659)
- Testing
- Glucagon
- Where
- United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- AdventHealth Translational Research Institute
Glucagon-like Peptide-1, Smoking Cessation
Smoking Cessation Facilitated by Glucagon-like Peptide-1 (GLP-1) Analogues
Cigarette smoking is the leading preventable cause of premature death worldwide. However smoking is a very difficult addiction to break whereby main reasons for not quitting or relapsing after cessation are the nicotine…
- Conditions
- Glucagon-like Peptide-1, Smoking Cessation, Weight Change, Body, Craving
- Trial name
- SKIP (NCT03204396)
- Testing
- Dulaglutide, 0.5 ml normal saline (0.9% sodium chloride [0.9% NaCl])
- Where
- Switzerland
- Volunteers
- 256 people, healthy volunteers welcome
- Sponsor
- University Hospital, Basel, Switzerland
Diabetic Kidney Disease, Diabetic Nephropathy
Effect of LIXIsenatide on the Renal System
Based on preclinical and small-sized studies in non-diabetic individuals, incretin-based therapies, i.e. glucagon-like peptide (GLP)-1 receptor agonists and dipeptidyl peptidase-4 inhibitors, may hold promise in preventing the…
- Conditions
- Diabetic Kidney Disease, Diabetic Nephropathy, Diabetes Mellitus, Glucagon-Like Peptide 1
- Trial name
- ELIXIRS (NCT02276196)
- Testing
- Lixisenatide, Insulin glulisine
- Where
- Netherlands
- Volunteers
- 40 people
- Sponsor
- Amsterdam UMC, location VUmc
Type 1 Diabetes
The Summer Camp Study: Blood Glucose Control With a Bi-Hormonal Bionic Endocrine Pancreas
This study will test the hypothesis that a wearable automated bionic pancreas system that automatically delivers both insulin and glucagon can improved glycemic control vs.
- Trial name
- NCT01833988
- Testing
- Bi-hormonal Bionic Pancreas, Usual Care
- Where
- United States
- Volunteers
- 32 people
- Sponsor
- Massachusetts General Hospital
Glucose Metabolism, Glucagon
Investigating the Acute Effects of Increasing Alanine Exposure in Healthy Participants
In this study the investigators will investigate the acute effects of increasing alanine exposure on metabolic parameters in healthy participants. Participants will participate in one study day.
- Trial name
- NCT07350512
- Testing
- alanine
- Where
- Denmark
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- Nicolai Jacob Wewer Albrechtsen
Psoriasis Arthritis
GLP-1 Receptor Agonists in Non-diabetic Patients With Psoriatic Arthritis
Background Psoriatic arthritis (PsA) patients are at increased risk of cardiovascular disease. Glucagon-Like Peptide-1 (GLP-1) receptor agonists are cardiovascular protective in diabetics.
- Trial name
- NCT07251556
- Testing
- Semaglutide 0.5 mg, Semaglutide 1.0 mg, Semaglutide 0.25 mg
- Volunteers
- 40 people
- Sponsor
- Chinese University of Hong Kong
Type 2 Diabetes Mellitus (T2DM)
Dose-Ranging Study to Evaluate Efficacy and Safety of Weekly CJC-1134-PC in Patients With T2DM on Metformin Monotherapy
DM200-103 is a dose-ranging study to evaluate the efficacy and safety of 17 weeks of weekly injections of CJC-1134-PC in patients with Type 2 Diabetes Mellitus on metformin monotherapy.
- Trial name
- NCT01514149
- Testing
- CJC-1134-PC Injection
- Where
- 22 sites in United States, Canada
- Volunteers
- 73 people
- Sponsor
- ConjuChem
Severe Hypoglycemia, Type1diabetes
Longitudinal Study of the GLUcagon REsponse to Hypoglycemia in Children and Adolescents With New-onset Type 1 DIAbetes
The GLUREDIA study investigates the counter-regulatory response (CRR) during hypoglycemia in children with type 1 diabetes (T1D).
- Trial name
- GLUREDIA (NCT06770621)
- Testing
- Insulin-induced hypoglycemia test, Glucagon profile, Biological sample once
- Where
- Belgium
- Volunteers
- 1,000 people, healthy volunteers welcome
- Sponsor
- Cliniques universitaires Saint-Luc- Université Catholique de Louvain
Hypoglycemia
Safety and Efficacy Study of Mini-Dose Glucagon (G-Pen Mini) in Patients With Type 1 Diabetes
The purpose of the study is to demonstrate that mini-doses of stable liquid glucagon (G-Pen Mini) produced by Xeris Pharmaceuticals are safe and effective as a treatment for mild to moderate hypoglycemia, a complication of…
- Trial name
- NCT02081014
- Testing
- G-Pen Mini™ (glucagon injection)
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- Xeris Pharmaceuticals
Type 2 Diabetes Mellitus
A Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes Not Controlled With Diet and Exercise Alone
The goal for this study is to evaluate the efficacy and safety of tirzepatide versus placebo in participants with type 2 diabetes not under control with diet and exercise alone.
- Trial name
- SURPASS-1 (NCT03954834)
- Testing
- Tirzepatide
- Where
- 53 sites in United States, India and 3 more
- Volunteers
- 478 people
- Sponsor
- Eli Lilly and Company
Type 1 Diabetes Mellitus
Insulin NovoRapid Versus Actrapid in Treatment of Type 1 Diabetic Patients During Daily Adjustment of Insulin Dose
The main purpose of the study is to investigate the reason for the reduced number of hypoglycaemic attacks in type 1 diabetic patients when, for a period of time, using Insulin Aspart at meals together with NPH insulin mornings…
- Trial name
- NCT00145353
- Testing
- Insulin NovoRapid versus Actrapid
- Where
- Denmark
- Volunteers
- 16 people
- Sponsor
- Odense University Hospital
Endocrine System Diseases
Oral Glucose Stimulation in Normal-weight and Obese Volunteers
The objective of this study is to examine gastric emptying and satiety hormones after oral glucose stimulation in 2 different concentrations in normal-weight and obese patients.
- Trial name
- NCT01875575
- Testing
- Glucose 25g, Glucose 10g
- Where
- Switzerland
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- University Hospital, Basel, Switzerland